Collectively, these findings demonstrate that the HSD17B12-derived peptide effectively down-regulates PD-L1 and suppresses tumor progression in vivo, suggesting the potential of HSD17B12 as a novel therapeutic target for cancer. This evidence concerns the gene CD274 and cancer.